Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimasertib plus FOLFIRI in metastatic KRAS mutated colorectal cancer
NCT01085331Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Mar 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pimasertib in colorectal cancer (metastatic) (mCRC), sponsored by EMD Serono. Started Mar 2010; status: terminated.
02
Drugs
pimasertib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01085331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085331.